As the US Supreme Court readies to officially rule on the so-called pay-for-delay schemes used by brand name drug companies to keep the often cheaper generic forms off the shelves, analysts are reportedly expecting ongoing complexities to emerge from the ruling. Further, the ruling will likely lead to more litigation to contest the deals by both the Federal Trade Commission and private parties. The Federal Trade Commission maintains that the pay-for-delay deals violate antitrust law and prevent consumers from having access to less expensive medications. Analysts are torn as to which way the Court is likely to rule.
Featured News
Importers Sue Shipping Container Makers Over Alleged Price-Fixing Scheme
Jun 10, 2026 by
CPI
Brazil Fines Denso $19.5 Million for Role in Auto Parts Cartel
Jun 10, 2026 by
CPI
UK Competition Watchdog Opens Formal Review of Paramount Skydance-Warner Bros Discovery Deal
Jun 10, 2026 by
CPI
New York’s Synthetic Performer Disclosure Law Raises Compliance Stakes for Advertisers
Jun 10, 2026 by
CPI
Congress Weighs How Colleges Should Handle AI
Jun 10, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – (Geo)Political Antitrust
May 28, 2026 by
CPI
Competition Policy in Turbulent Geopolitical Times
May 28, 2026 by
Christophe Carugati & Annabelle Gawer
The New Political Determinants of U.S. Antitrust Policy
May 28, 2026 by
Aziz Z. Huq
The Geopolitical Rewiring of Antitrust
May 28, 2026 by
Hayane C. Dahmen
Three Strikes Against Political Antitrust
May 28, 2026 by
Nolan McCarty & Sepehr Shahshahani